I dont think we're being ignored. It's more like big
I dont think we're being ignored. It's more like big pharma gets their bite at the apple first no matter how much better lero is compared to their candidates. Its really how the world works if you think about it. We're taught fairness as a benchmark, but we see that this is typically not the case in practice. And to be fair to big pharma, they did get to where they are by producing good product at some time in the past. Its just that they abuse their position and power for their own interest instead of the greater good. Corruption always enters any system left alone too long. I believe in what the FDA does, but it needs an overhaul to scrape off the rust of corruption. Maybe overhaul every 5-10 years.
Oops, got off point which is that we'll get our chance eventually...hopefully not before too many more die.
My FU to the FDA post wasn't meant to be taken to abandon them, but to show them they need to change their ways. If they see other countries using lero and seeing their citizens get better, I think FDA or at least their regulators will see that changes are needed.
2
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Hong Kong Wine & Dine Festival Returns This October HONG KONG, an anticipated gastronomic spectacle is set for the latter part of October. The Hong Kong Wine & Dine Festival will take place from 23 to 26 October 2025 at the iconic Central Harbourfront. This annual celebration is designed to showcase the best in culinary arts and exquisite wines, offering something special...
Continue Reading
Danaher Sets Date for Q3 2024 Earnings Conference Call Danaher Corporation (NYSE: DHR) has announced the date for its highly anticipated quarterly earnings conference call. This event is significant for investors and stakeholders who keep a close eye on the company's developments. Earnings Call Details The earnings call is set for an upcoming Tuesday morning, during which...
Continue Reading
UniQure Stock Reaches New Heights UniQure NV (QURE) has exciting news as its stock recently touched an impressive 52-week high of $18.5. This remarkable milestone is a testament to the company's resilient growth strategy and innovative advancements in the biotechnology industry. With a market capitalization reaching $885 million, the stock has seen an astonishing rise of...
Continue Reading
MedCana Enters Negotiations for Cannabis Supply Agreement MedCana, a prominent player in the pharmaceutical-grade cannabis landscape, is making headlines with an exciting new development from its subsidiary in Colombia. The company is set to negotiate a substantial supply agreement worth between $1.2 million and $2.4 million annually. This agreement marks a significant...
Continue Reading
Mouawad Teams Up with OCTA Properties for Luxe Residences OCTA Properties has been selected as the global licensee for residences branded by Mouawad, bringing the brand's legacy of timeless elegance into the realm of premium real estate. This partnership marks an exciting new chapter in Mouawad's prestigious journey in luxury development. A Landmark Collaboration Mouawad,...
Continue Reading
